Small molecule · Immune activation, directed at Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8) · developed by Eikon Therapeutics
Resiquimod is a small molecule that binds and activates Toll-like receptors 7 and 8, stimulating maturation of antigen-presenting cells such as dendritic cells and the production of pro-inflammatory cytokines. It is being studied in solid tumors, including pancreatic cancer, non-small cell lung cancer, melanoma, bladder cancer and triple negative breast cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07365319 | Phase 2/3 | Non Small Cell Lung Cancer (Squamous or Non Squamous) | Recruiting | EIKN |
| NCT04819373 | Phase 2 | Tumor, Solid | Completed | EIKN |
| NCT03915678 | Phase 2 | Solid Tumor, Adult | Active not recruiting | EIKN |
| NCT03486301 | Phase 1 | Tumor, Solid | Completed | EIKN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Bladder CancerMelanomaNon Small Cell Lung CancerNon Small Cell Lung Cancer (Squamous or Non Squamous)Pancreatic CancerSolid Tumor, AdultStage 4 NSCLCTriple Negative Breast CancerVirus-associated TumorsTumor, Solid
Updated Oct 11, 2026. Something wrong or missing? Report it on the EIKN page.
See EIKN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
EIKN catalysts and pipeline →